<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33442016</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Immune determinants of COVID-19 disease presentation and severity.</ArticleTitle><Pagination><StartPage>28</StartPage><EndPage>33</EndPage><MedlinePgn>28-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-020-01202-8</ELocationID><Abstract><AbstractText>COVID-19, caused by SARS-CoV-2 infection, is mild to moderate in the majority of previously healthy individuals, but can cause life-threatening disease or persistent debilitating symptoms in some cases. The most important determinant of disease severity is age, with individuals over 65 years having the greatest risk of requiring intensive care, and men are more susceptible than women. In contrast to other respiratory viral infections, young children seem to be less severely affected. It is now clear that mild to severe acute infection is not the only outcome of COVID-19, and long-lasting symptoms are also possible. In contrast to severe acute COVID-19, such 'long COVID' is seemingly more likely in women than in men. Also, postinfectious hyperinflammatory disease has been described as an additional outcome after SARS-CoV-2 infection. Here I discuss our current understanding of the immunological determinants of COVID-19 disease presentation and severity and relate this to known immune-system differences between young and old people and between men and women, and other factors associated with different disease presentations and severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brodin</LastName><ForeName>Petter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8103-0046</Identifier><AffiliationInfo><Affiliation>Science for Life Laboratory, Department. of Women's and Children's Health, Karolinska Institutet, Solna, Sweden. petter.brodin@ki.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Rheumatology, Karolinska University Hospital, Solna, Sweden. petter.brodin@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="N">Adaptive Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007153" MajorTopicYN="N">Immunologic Deficiency Syndromes</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>14</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33442016</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-01202-8</ArticleId><ArticleId IdType="pii">10.1038/s41591-020-01202-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Doremalen, N. et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N. Engl. J. Med. 382, 1564&#x2013;1567 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32182409</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2004973</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497&#x2013;506 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId><ArticleId IdType="pmc">7159299</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465&#x2013;469 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32235945</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadas, S. M. et al. The implications of silent transmission for the control of COVID-19 outbreaks. Proc. Natl Acad. Sci. USA 117, 17513&#x2013;17515 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32632012</ArticleId><ArticleId IdType="doi">10.1073/pnas.2008373117</ArticleId><ArticleId IdType="pmc">7395516</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin, P. Why is COVID&#x2010;19 so mild in children? Acta Paediatr. 109, 1082&#x2013;1083 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32212348</ArticleId><ArticleId IdType="doi">10.1111/apa.15271</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315&#x2013;320 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32846427</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2700-3</ArticleId><ArticleId IdType="pmc">7725931</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect. Dis. 20, 656&#x2013;657 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32199493</ArticleId><ArticleId IdType="pmc">7158902</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(20)30232-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, J. C. et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev. Cell 53, 514&#x2013;529(2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32425701</ArticleId><ArticleId IdType="pmc">7229915</ArticleId><ArticleId IdType="doi">10.1016/j.devcel.2020.05.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033&#x2013;1034 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId><ArticleId IdType="pmc">7270045</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269&#x2013;270 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32273594</ArticleId><ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId><ArticleId IdType="pmc">7143200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with implications for therapeutic interventions. Science 369, eabc8511 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32669297</ArticleId><ArticleId IdType="pmc">7402624</ArticleId><ArticleId IdType="doi">10.1126/science.abc8511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas, C. et al. Longitudinal immunological analyses reveal inflammatory misfiring in severe COVID-19 patients. Nature 584, 463&#x2013;469 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32717743</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">7477538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez, L. et al. Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. Cell Rep. Med. 1, 100078 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32838342</ArticleId><ArticleId IdType="pmc">7405891</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2020.100078</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec;, A. et al. Persistent symptoms in patients after acute COVID-19. JAMA 324, 603&#x2013;605 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32644129</ArticleId><ArticleId IdType="pmc">7349096</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis, A. et al. Multi-organ impairment in low-risk individuals with long COVID. Preprint at medRxiv https://doi.org/10.1101/2020.10.14.20212555 (2020).</Citation></Reference><Reference><Citation>Ludvigsson, J. F. Case report and systematic review suggest that children may experience similar long&#x2010;term effects to adults after clinical COVID&#x2010;19. Acta Paediatr. https://doi.org/10.1111/apa.15673 (2020).</Citation></Reference><Reference><Citation>Davido, B., Seang, S., Tubiana, R. &amp; de Truchis, P. Post-COVID-19 chronic symptoms: a post-infectious entity? Clin. Microbiol. Infec. 26, 1448&#x2013;1449 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot, X., Ribera, A. &amp; Gasque, P. Chikungunya-induced arthritis in Reunion Island: a long-term observational follow-up study showing frequently persistent joint symptoms, some cases of persistent chikungunya immunoglobulin M positivity, and no anticyclic citrullinated peptide seroconversion after 13 years. J. Infect. Dis. 222, 1740&#x2013;1744 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32428203</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiaa261</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark, D. V. et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect. Dis. 15, 905&#x2013;912 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25910637</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(15)70152-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie, I. et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 333, 575 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16950834</ArticleId><ArticleId IdType="pmc">1569956</ArticleId><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez, L. S. T. et al. Achieving symptom relief in patients with Myalgic encephalomyelitis by targeting the neuro-immune interface and inducing disease tolerance. Preprint at bioRxiv https://doi.org/10.1101/2020.02.20.958249 (2020).</Citation></Reference><Reference><Citation>Whittaker, E. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 324, 259&#x2013;269 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10369</ArticleId><ArticleId IdType="pubmed">32511692</ArticleId><ArticleId IdType="pmc">7281356</ArticleId></ArticleIdList></Reference><Reference><Citation>Belot, A. et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro. Surveill. 25, 2001010 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">7336112</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.22.2001010</ArticleId></ArticleIdList></Reference><Reference><Citation>Toubiana, J. et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. BMJ 369, m2094 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32493739</ArticleId><ArticleId IdType="pmc">7500538</ArticleId><ArticleId IdType="doi">10.1136/bmj.m2094</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris, S. B. et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection&#x2014;United Kingdom and United States, March&#x2013;August 2020. Morbidity Mortal. Wkly Rep. 69, 1450&#x2013;1456 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6940e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrani, E., Burns, J. C. &amp; Cimaz, R. How should we classify Kawasaki disease? Front Immunol. 9, 2974 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30619331</ArticleId><ArticleId IdType="pmc">6302019</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.02974</ArticleId></ArticleIdList></Reference><Reference><Citation>Corwin, D. J. et al. Distinguishing multisystem inflammatory syndrome in children from Kawasaki disease and benign inflammatory illnesses in the SARS-CoV-2 pandemic. Pediatr. Emerg. Care 36, 554&#x2013;558 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32970023</ArticleId><ArticleId IdType="doi">10.1097/PEC.0000000000002248</ArticleId><ArticleId IdType="pmc">8555855</ArticleId></ArticleIdList></Reference><Reference><Citation>Diorio, C. et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J. Clin. Invest. 130, 5967&#x2013;5975 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32730233</ArticleId><ArticleId IdType="doi">10.1172/JCI140970</ArticleId><ArticleId IdType="pmc">7598044</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio, C. R. et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 183, 968&#x2013;981 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32966765</ArticleId><ArticleId IdType="pmc">7474869</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.09.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio, C. R. &amp; Brodin, P. Stressful beginnings with long-term consequences. Cell 180, 820&#x2013;821 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32142672</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.02.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber, C. et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell 183, 982&#x2013;995 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32991843</ArticleId><ArticleId IdType="pmc">7489877</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.09.034</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271&#x2013;280 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId><ArticleId IdType="pmc">7102627</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, H. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral. Sci. 12, 8 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32094336</ArticleId><ArticleId IdType="pmc">7039956</ArticleId><ArticleId IdType="doi">10.1038/s41368-020-0074-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi, F., Qian, S., Zhang, S. &amp; Zhang, Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem. Bioph. Res. Co. 526, 135&#x2013;140 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.03.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631&#x2013;637 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15141377</ArticleId><ArticleId IdType="pmc">7167720</ArticleId><ArticleId IdType="doi">10.1002/path.1570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hikmet, F. et al. The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 16, e9610 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32715618</ArticleId><ArticleId IdType="pmc">7383091</ArticleId><ArticleId IdType="doi">10.15252/msb.20209610</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Y. et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med. 26, 502&#x2013;505 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32284613</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0817-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen, M. et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science 366, eaax9198 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31857451</ArticleId><ArticleId IdType="doi">10.1126/science.aax9198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim, Y., Ng, Y., Tam, J. &amp; Liu, D. Human coronaviruses: a review of virus&#x2013;host interactions. Diseases 4, 26 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">5456285</ArticleId><ArticleId IdType="doi">10.3390/diseases4030026</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald, K. A. &amp; Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180, 1044&#x2013;1066 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32164908</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.02.041</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto-Torres, J. L. et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology 485, 330&#x2013;339 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26331680</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2015.08.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues, T.S. et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 218, e20201707 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33231615</ArticleId><ArticleId IdType="doi">10.1084/jem.20201707</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, Y. et al. Lactate dehydrogenase, a risk factor of severe COVID-19 patients. Aging 12, 11245&#x2013;11258 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32633729</ArticleId><ArticleId IdType="pmc">7343511</ArticleId><ArticleId IdType="doi">10.18632/aging.103372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, C. et al. Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity 50, 1401&#x2013;1411 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31076358</ArticleId><ArticleId IdType="pmc">6791531</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2019.04.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp, S. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemost. 18, 1995&#x2013;2002 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32369666</ArticleId><ArticleId IdType="pmc">7497052</ArticleId><ArticleId IdType="doi">10.1111/jth.14888</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh, T., Knight, M., A&#x2019;Court, C., Buxton, M. &amp; Husain, L. Management of post-acute COVID-19 in primary care. BMJ 370, m3026 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;st, R. et al. Ribose 2&#x2032;-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 12, 137&#x2013;143 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21217758</ArticleId><ArticleId IdType="pmc">3182538</ArticleId><ArticleId IdType="doi">10.1038/ni.1979</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel, M. et al. Inhibition of beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J. Virol. 79, 2079&#x2013;2086 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15681410</ArticleId><ArticleId IdType="pmc">546554</ArticleId><ArticleId IdType="doi">10.1128/JVI.79.4.2079-2086.2005</ArticleId></ArticleIdList></Reference><Reference><Citation>Miorin, L. et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc. Natl. Acad Sci. USA 117, 28344&#x2013;28354 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33097660</ArticleId><ArticleId IdType="doi">10.1073/pnas.2016650117</ArticleId><ArticleId IdType="pmc">7668094</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 1210&#x2013;1220 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32788292</ArticleId><ArticleId IdType="pmc">7665312</ArticleId><ArticleId IdType="doi">10.1126/science.abc6261</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036&#x2013;1045 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32416070</ArticleId><ArticleId IdType="pmc">7227586</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463&#x2013;469 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32717743</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">7477538</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity 52, 910&#x2013;941 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32505227</ArticleId><ArticleId IdType="pmc">7200337</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2020.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova, J.-L., Su, H. C. &amp; COVID Human Genetic Effort. A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell 181, 1194&#x2013;199 (2020).</Citation></Reference><Reference><Citation>Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId><ArticleId IdType="pmc">7857407</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P. et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId><ArticleId IdType="pmc">7857397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson, D. F. et al. Humoral immune response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 383, 1724&#x2013;1734 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32871063</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2026116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, eabd7728 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd7728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley, S. F. et al. Antibodies to SARS-CoV-2 are associated with protection against reinfection. Preprint at medRxiv https://doi.org/10.1101/2020.11.18.20234369 (2020).</Citation></Reference><Reference><Citation>Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489&#x2013;1501 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32473127</ArticleId><ArticleId IdType="pmc">7237901</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, L. F., Kidd, B. A., Han, A., Kotzin, J. J. &amp; Davis, M. M. Virus-specific CD4+ memory-phenotype T cells are abundant in unexposed adults. Immunity 38, 373&#x2013;83 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23395677</ArticleId><ArticleId IdType="pmc">3626102</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2012.10.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Bert, N. L. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457&#x2013;462 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32668444</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetro, J. A. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 22, 72&#x2013;73 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32092539</ArticleId><ArticleId IdType="pmc">7102551</ArticleId><ArticleId IdType="doi">10.1016/j.micinf.2020.02.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan, Y. et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J. Virol. 94, e02015&#x2013;e02019 (2019).</Citation></Reference><Reference><Citation>Iwasaki, A. What reinfections mean for COVID-19. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(20)30783-0 (2020).</Citation></Reference><Reference><Citation>Lipsitch, M., Grad, Y. H., Sette, A. &amp; Crotty, S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat. Rev. Immunol. 20, 709&#x2013;713 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33024281</ArticleId><ArticleId IdType="doi">10.1038/s41577-020-00460-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89&#x2013;94 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32753554</ArticleId><ArticleId IdType="pmc">7574914</ArticleId><ArticleId IdType="doi">10.1126/science.abd3871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, K. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370, eabe1107 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe1107</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Preprint at medRxiv https://doi.org/10.1101/2020.11.06.20227215 (2020).</Citation></Reference><Reference><Citation>Tso, F. Y. et al. High prevalence of pre-existing serological cross-reactivity against SARS-CoV-2 in sub-Sahara Africa. Int. J. Infect. Dis. 102, 577&#x2013;583 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33176202</ArticleId><ArticleId IdType="pmc">7648883</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2020.10.104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostad, C. A. et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C). Pediatrics 146, e2020018242 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32879033</ArticleId><ArticleId IdType="doi">10.1542/peds.2020-018242</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisberg, S. P. et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. https://doi.org/10.1038/s41590-020-00826-9 (2020).</Citation></Reference><Reference><Citation>Pierce, C. A. et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci. Transl. Med. 564, eabd5487 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd5487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergh&#xf6;fer, B. et al. TLR7 ligands induce higher IFN-&#x3b1; production in females. J. Immunol. 177, 2088&#x2013;2096 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16887967</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.177.4.2088</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, S. L., Marriott, I. &amp; Fish, E. N. Sex-based differences in immune function and responses to vaccination. Trans. R. Soc. Trop. Med. H. 109, 9&#x2013;15 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/trstmh/tru167</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, S. L., Jedlicka, A. &amp; Pekosz, A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 10, 338&#x2013;349 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20417416</ArticleId><ArticleId IdType="pmc">6467501</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(10)70049-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb, K. et al. Sex and pubertal differences in the type 1 interferon pathway associate with both X chromosome number and serum sex hormone concentration. Front Immunol. 9, 3167 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30705679</ArticleId><ArticleId IdType="pmc">6345344</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.03167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmann, T. R., Levy, O., Montgomery, R. R. &amp; Goriely, S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 37, 771&#x2013;783 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23159225</ArticleId><ArticleId IdType="pmc">3538030</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2012.10.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertz, D. et al. Pregnancy as a risk factor for severe outcomes from influenza virus infection: a systematic review and meta-analysis of observational studies. Vaccine 35, 521&#x2013;528 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28024955</ArticleId><ArticleId IdType="pmc">5359513</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2016.12.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pido-Lopez, J., Imami, N. &amp; Aspinall, R. Both age and gender affect thymic output: more recent thymic migrants in females than males as they age. Clin. Exp. Immunol. 125, 409&#x2013;413 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11531948</ArticleId><ArticleId IdType="pmc">1906152</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2249.2001.01640.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Saso, A. &amp; Kampmann, B. Vaccine responses in newborns. Semin. Immunopathol. 39, 627&#x2013;642 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29124321</ArticleId><ArticleId IdType="pmc">5711983</ArticleId><ArticleId IdType="doi">10.1007/s00281-017-0654-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagunas-Rangel, F. A. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J. Med. Virol. 92, 1733&#x2013;1734 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32242950</ArticleId><ArticleId IdType="doi">10.1002/jmv.25819</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J. et al. Neutrophil-to-lymphocyte ratio positively correlates to age in healthy population. J. Clin. Lab Anal. 29, 437&#x2013;43 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25277347</ArticleId><ArticleId IdType="pmc">6807196</ArticleId><ArticleId IdType="doi">10.1002/jcla.21791</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz, H. et al. Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity. Diabetes Metab. Syndr. Clin. Res. Rev. 9, 299&#x2013;304 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2014.04.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Molony, R. D. et al. Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes. Sci. Signal. 10, eaan2392 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29233916</ArticleId><ArticleId IdType="pmc">6429941</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aan2392</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle, D., Sharif, K., O&#x2019;Regan, A. &amp; Bridgewood, C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 19, 102537 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32251717</ArticleId><ArticleId IdType="pmc">7195002</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2020.102537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, R. et al. HMGB1 in health and disease. Mol. Asp. Med. 40, 1&#x2013;116 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2014.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, Y., Chen, Y., Liu, M., Shi, S. &amp; Tian, J. Impacts of immunosuppression and immunodeficiency on COVID-19: a systematic review and meta-analysis. J. Infection. 81, 93&#x2013;95 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.05.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung, M. &amp; Babik, J. M. COVID-19 in immunocompromised hosts: what we know so far. Clin. Infect. Dis. ciaa863 (2020).</Citation></Reference><Reference><Citation>Robilotti, E. V. et al. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 26, 1218&#x2013;1223 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32581323</ArticleId><ArticleId IdType="pmc">7785283</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0979-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinti, I. et al. A possible role for B cells in COVID-19?: lesson from patients with Agammaglobulinemia. J. Allergy Clin. Immunol. 146, 211&#x2013;213 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32333914</ArticleId><ArticleId IdType="pmc">7175894</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2020.04.013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>